Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Peripheral 4Lymphoma, T-Cell 4Lymphoma, Large-Cell, Anaplastic 3Recurrence 2Multiple Myeloma 2Lymphoma, Follicular 2Immunoblastic Lymphadenopathy 2Esophageal Squamous Cell Carcinoma 2Adenocarcinoma Of Esophagus 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Subcutaneous panniculitis-like T-cell lymphoma 1Stomach Neoplasms 1Ovarian Neoplasms 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Enteropathy-Associated T-Cell Lymphoma 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1

Interventions

pembrolizumab 2Vorinostat 2Vincristine 2Prednisone 2Doxorubicin 2Cyclophosphamide 2Bortezomib 2prednylidene 1pirarubicin 1etoposide phosphate 1Salvia hispanica seed extract 1Methotrexate 1Ifosfamide 1Everolimus 1Etoposide 1Cholecalciferol 1Brentuximab Vedotin 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Subcutaneous panniculitis-like T-cell lymphoma × 10-propargyl-10-deazaaminopterin × Clear all
NCT03598998 2026-05-26

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

City of Hope Medical Center

Phase 1/2 Active not recruiting
13 enrolled 12 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡